EUROFINS SCIENTIFIC (ERF.PA) Stock Fundamental Analysis
Europe - EPA:ERF - FR0014000MR3 - Common Stock
58.96 EUR
-0.54 (-0.91%)
ERF gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 18 industry peers in the Life Sciences Tools & Services industry. ERF has an average financial health and profitability rating. ERF scores decently on growth, while it is valued quite cheap. This could make an interesting combination. These ratings could make ERF a good candidate for value investing.
1. Profitability
1.1 Basic Checks
ERF had positive earnings in the past year.
In the past year ERF had a positive cash flow from operations.
ERF had positive earnings in each of the past 5 years.
Each year in the past 5 years ERF had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 3.54%, ERF is in line with its industry, outperforming 47.37% of the companies in the same industry.
ERF has a Return On Equity (8.09%) which is comparable to the rest of the industry.
ERF has a Return On Invested Capital of 9.79%. This is in the better half of the industry: ERF outperforms 73.68% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ERF is significantly below the industry average of 13.84%.
The last Return On Invested Capital (9.79%) for ERF is above the 3 year average (8.70%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.54% | ||
| ROE | 8.09% | ||
| ROIC | 9.79% |
ROA(3y)3.79%
ROA(5y)5.05%
ROE(3y)7.94%
ROE(5y)10.72%
ROIC(3y)8.7%
ROIC(5y)10.54%
1.3 Margins
The Profit Margin of ERF (5.44%) is worse than 63.16% of its industry peers.
ERF's Profit Margin has improved in the last couple of years.
ERF's Operating Margin of 15.59% is in line compared to the rest of the industry. ERF outperforms 52.63% of its industry peers.
In the last couple of years the Operating Margin of ERF has grown nicely.
ERF's Gross Margin of 23.29% is on the low side compared to the rest of the industry. ERF is outperformed by 84.21% of its industry peers.
ERF's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.59% | ||
| PM (TTM) | 5.44% | ||
| GM | 23.29% |
OM growth 3Y-11.93%
OM growth 5Y3.56%
PM growth 3Y-23.05%
PM growth 5Y9.75%
GM growth 3Y-7.6%
GM growth 5Y1.83%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ERF is still creating some value.
The number of shares outstanding for ERF has been reduced compared to 1 year ago.
ERF has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ERF has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.64 indicates that ERF is not a great score, but indicates only limited risk for bankruptcy at the moment.
ERF has a Altman-Z score of 2.64. This is comparable to the rest of the industry: ERF outperforms 52.63% of its industry peers.
ERF has a debt to FCF ratio of 5.25. This is a neutral value as ERF would need 5.25 years to pay back of all of its debts.
The Debt to FCF ratio of ERF (5.25) is better than 63.16% of its industry peers.
A Debt/Equity ratio of 0.77 indicates that ERF is somewhat dependend on debt financing.
ERF has a Debt to Equity ratio of 0.77. This is in the lower half of the industry: ERF underperforms 73.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.77 | ||
| Debt/FCF | 5.25 | ||
| Altman-Z | 2.64 |
ROIC/WACC1.25
WACC7.85%
2.3 Liquidity
A Current Ratio of 1.26 indicates that ERF should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.26, ERF is doing worse than 63.16% of the companies in the same industry.
A Quick Ratio of 1.19 indicates that ERF should not have too much problems paying its short term obligations.
The Quick ratio of ERF (1.19) is better than 78.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.26 | ||
| Quick Ratio | 1.19 |
3. Growth
3.1 Past
ERF shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.50%, which is quite good.
Measured over the past years, ERF shows a quite strong growth in Earnings Per Share. The EPS has been growing by 18.34% on average per year.
Looking at the last year, ERF shows a small growth in Revenue. The Revenue has grown by 2.53% in the last year.
ERF shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.78% yearly.
EPS 1Y (TTM)16.5%
EPS 3Y-21.42%
EPS 5Y18.34%
EPS Q2Q%19.61%
Revenue 1Y (TTM)2.53%
Revenue growth 3Y1.14%
Revenue growth 5Y8.78%
Sales Q2Q%5.64%
3.2 Future
The Earnings Per Share is expected to grow by 15.60% on average over the next years. This is quite good.
Based on estimates for the next years, ERF will show a small growth in Revenue. The Revenue will grow by 7.37% on average per year.
EPS Next Y14.65%
EPS Next 2Y13.56%
EPS Next 3Y14%
EPS Next 5Y15.6%
Revenue Next Year5.1%
Revenue Next 2Y5.44%
Revenue Next 3Y5.91%
Revenue Next 5Y7.37%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
ERF is valuated correctly with a Price/Earnings ratio of 16.38.
Compared to the rest of the industry, the Price/Earnings ratio of ERF indicates a rather cheap valuation: ERF is cheaper than 84.21% of the companies listed in the same industry.
ERF is valuated rather cheaply when we compare the Price/Earnings ratio to 25.89, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 14.80, which indicates a correct valuation of ERF.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ERF indicates a rather cheap valuation: ERF is cheaper than 84.21% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 34.59. ERF is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.38 | ||
| Fwd PE | 14.8 |
4.2 Price Multiples
84.21% of the companies in the same industry are more expensive than ERF, based on the Enterprise Value to EBITDA ratio.
89.47% of the companies in the same industry are more expensive than ERF, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.7 | ||
| EV/EBITDA | 8.3 |
4.3 Compensation for Growth
ERF's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
ERF has a very decent profitability rating, which may justify a higher PE ratio.
ERF's earnings are expected to grow with 14.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.12
PEG (5Y)0.89
EPS Next 2Y13.56%
EPS Next 3Y14%
5. Dividend
5.1 Amount
ERF has a Yearly Dividend Yield of 1.01%. Purely for dividend investing, there may be better candidates out there.
ERF's Dividend Yield is rather good when compared to the industry average which is at 0.74. ERF pays more dividend than 89.47% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.44, ERF's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.01% |
5.2 History
The dividend of ERF is nicely growing with an annual growth rate of 16.51%!
Dividend Growth(5Y)16.51%
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
54.91% of the earnings are spent on dividend by ERF. This is a bit on the high side, but may be sustainable.
ERF's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP54.91%
EPS Next 2Y13.56%
EPS Next 3Y14%
EPA:ERF (11/14/2025, 7:00:00 PM)
58.96
-0.54 (-0.91%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners37.21%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap10.74B
Revenue(TTM)6.89B
Net Income(TTM)374.80M
Analysts69.47
Price Target64.78 (9.87%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.01% |
Yearly Dividend0.52
Dividend Growth(5Y)16.51%
DP54.91%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.48%
PT rev (3m)-0.17%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.09%
EPS NY rev (3m)-0.55%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.32%
Revenue NY rev (3m)-0.84%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.38 | ||
| Fwd PE | 14.8 | ||
| P/S | 1.56 | ||
| P/FCF | 13.7 | ||
| P/OCF | 8.17 | ||
| P/B | 2.32 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.3 |
EPS(TTM)3.6
EY6.11%
EPS(NY)3.98
Fwd EY6.76%
FCF(TTM)4.3
FCFY7.3%
OCF(TTM)7.22
OCFY12.24%
SpS37.84
BVpS25.45
TBVpS-3.69
PEG (NY)1.12
PEG (5Y)0.89
Graham Number45.4
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.54% | ||
| ROE | 8.09% | ||
| ROCE | 12.64% | ||
| ROIC | 9.79% | ||
| ROICexc | 10.74% | ||
| ROICexgc | 34.1% | ||
| OM | 15.59% | ||
| PM (TTM) | 5.44% | ||
| GM | 23.29% | ||
| FCFM | 11.37% |
ROA(3y)3.79%
ROA(5y)5.05%
ROE(3y)7.94%
ROE(5y)10.72%
ROIC(3y)8.7%
ROIC(5y)10.54%
ROICexc(3y)9.52%
ROICexc(5y)11.6%
ROICexgc(3y)31.02%
ROICexgc(5y)39.55%
ROCE(3y)11.31%
ROCE(5y)13.7%
ROICexgc growth 3Y-18.17%
ROICexgc growth 5Y3.78%
ROICexc growth 3Y-15.5%
ROICexc growth 5Y6.63%
OM growth 3Y-11.93%
OM growth 5Y3.56%
PM growth 3Y-23.05%
PM growth 5Y9.75%
GM growth 3Y-7.6%
GM growth 5Y1.83%
F-Score7
Asset Turnover0.65
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.77 | ||
| Debt/FCF | 5.25 | ||
| Debt/EBITDA | 2.1 | ||
| Cap/Depr | 84.94% | ||
| Cap/Sales | 7.7% | ||
| Interest Coverage | 9.93 | ||
| Cash Conversion | 77.37% | ||
| Profit Quality | 209.21% | ||
| Current Ratio | 1.26 | ||
| Quick Ratio | 1.19 | ||
| Altman-Z | 2.64 |
F-Score7
WACC7.85%
ROIC/WACC1.25
Cap/Depr(3y)89.21%
Cap/Depr(5y)85.64%
Cap/Sales(3y)8.63%
Cap/Sales(5y)7.99%
Profit Quality(3y)162.79%
Profit Quality(5y)158.88%
High Growth Momentum
Growth
EPS 1Y (TTM)16.5%
EPS 3Y-21.42%
EPS 5Y18.34%
EPS Q2Q%19.61%
EPS Next Y14.65%
EPS Next 2Y13.56%
EPS Next 3Y14%
EPS Next 5Y15.6%
Revenue 1Y (TTM)2.53%
Revenue growth 3Y1.14%
Revenue growth 5Y8.78%
Sales Q2Q%5.64%
Revenue Next Year5.1%
Revenue Next 2Y5.44%
Revenue Next 3Y5.91%
Revenue Next 5Y7.37%
EBIT growth 1Y14.03%
EBIT growth 3Y-10.93%
EBIT growth 5Y12.66%
EBIT Next Year86.11%
EBIT Next 3Y30.34%
EBIT Next 5Y22.42%
FCF growth 1Y113.13%
FCF growth 3Y-7.69%
FCF growth 5Y25.62%
OCF growth 1Y31.31%
OCF growth 3Y-4.44%
OCF growth 5Y14.24%
EUROFINS SCIENTIFIC / ERF.PA FAQ
What is the ChartMill fundamental rating of EUROFINS SCIENTIFIC (ERF.PA) stock?
ChartMill assigns a fundamental rating of 6 / 10 to ERF.PA.
Can you provide the valuation status for EUROFINS SCIENTIFIC?
ChartMill assigns a valuation rating of 7 / 10 to EUROFINS SCIENTIFIC (ERF.PA). This can be considered as Undervalued.
Can you provide the profitability details for EUROFINS SCIENTIFIC?
EUROFINS SCIENTIFIC (ERF.PA) has a profitability rating of 6 / 10.
How financially healthy is EUROFINS SCIENTIFIC?
The financial health rating of EUROFINS SCIENTIFIC (ERF.PA) is 5 / 10.
Is the dividend of EUROFINS SCIENTIFIC sustainable?
The dividend rating of EUROFINS SCIENTIFIC (ERF.PA) is 4 / 10 and the dividend payout ratio is 54.91%.